The miR-200c-positive breast cancer cell line BT-474 was treated with doxorubicin for three rounds, which resulted in reduced miR-200c (Figure 1E) and elevated K-ras protein levels (Figure 1F) suggesting a miR-200c-dependent regulation of KRAS. The gene discussed is KRAS; the disease is breast cancer.